Glaxo makes progress on diabetes drug

published 3 April 2012

Drugs giant GlaxoSmithKline has received top-line results from seven of the eight 'Harmony' drug development Phase III studies investigating the use of albiglutide in type 2 diabetes.

Glaxo said that based on the studies it has performed so far, there is enough information to support progression to regulatory submissions, as a possible once-weekly treatment for type 2 diabetes. As well as the full data set from the Harmony 6, 7 and 8 development programme studies and the two-year data currently in-house from the five ongoing studies, a meta-analysis of cardiovascular safety data will be required to complete the registration package, consistent with US Food and Drug Administration guidelines.